Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06191263
Title Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ryvu Therapeutics SA
Age Groups: senior | adult
Covered Countries ITA | FRA | ESP

No variant requirements are available.